EBITDA margin is at 18.4 per cent
A report compiled by Fortune, Cadila’s total income at Rs 16,041 million grew by 15.3 per cent Y-o-Y, primarily driven by Zydus Wellness and emerging markets. Earnings Before Interest, Taxes, Depreciation, and Amortization margin came in at 18.4 per cent.
A PAT at Rs 2710 million grew by 95.6 per cent QoQ due to a lower interest cost, depreciation and tax reversals due to MAT credit during the quarter. Cadila domestic business posted 15 per cent Y-o-Y growth aided primarily by Zydus Welness. Domestic formulations segment grew slower than preceeding quarters at 14.4 per cent YoY. Company continues to grow above the market in the domestic formulations space. Domestic market growth was 7.8 per cent in Q4F13. Company’s formulations growth was staggering at 22.6 per cent in FY13.
Biochem growth has also picked up during the course of FY13 as the restructuring done by management is now paying dividends. Zydus Wellness was outperformer during the quarter growing at 26.5 per cent YoY. Management has indicated that Sugarfree and Everyuth sales have picked up during the course of FY13. The animal healthcare business grew by 6.7 per cent Y-o-Y.
Exports grew by 19.7 per cent Y-o-Y primarily led by emerging markets and European formulations business which grew by stellar 85.6 per cent and 36.1 per cent Y-o-Y.
EP News Bureau-Mumbai